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ABSTRACT 
1. BACKGROUND AND SETTING 
The study was conducted at Vryheid in the Kwazulu-Natal province. The increasing 
number of TB patients at Vryheid hospital’s OPD and wards has prompted me to 
assess the effectiveness of TB treatment by comparing the treatment outcomes 
between community-based DOTS (COMDOTS) and facility-based DOTS 
(FACDOTS). 2 main primary health care clinics were selected for the research 
(Bhekuzulu and Mason clinics). 
 
2. AIM 
This thesis evaluated the effectiveness and efficacy of DOTS strategy by comparing 
the outcomes of tuberculosis treatment of patients under DOTS at VRYHEID during 
2007: facility based versus community based DOTS. 
 
3. METHODS  
The research question of the study was “Does community-based DOTS offer better 
TB treatment outcomes than the facility-based group?                                                                 
This is a retrospective cohort study with a total sample size of 809 patients; retrieved 
from the records of 2 major clinics at Vryheid (TB registers) during 2007. A sample of 
396 patients was required in each group to determine a difference of 10 % (with a 
power of 90%) between the two groups of the study: community-based versus 
facility-based. Mason clinic has mostly patients on facility-based DOTS whereas the 
patients involved in community-based approach were found at Bhekuzulu clinic. 
 
4. RESULTS 
The 2 groups of the study (COMDOTS and FACDOTS) were comparable in terms of 
age and gender composition. 
52% of patients in the community-based group completed their TB treatment and 
only 37.7% in the facility-based group. 
14% of patients died in the community-based DOTS group versus 6.1% in the 
facility-based group.  
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4.5% of community-based group defaulted medications, as compared to 1.7% in the 
facility-based group. 
34.8% of facility-based DOTS interrupted treatment whereas the percentage is lower 
in the community-based group (1%). 
The community-based group had a failure rate of 6% versus 3.7% in the facility-
based. 
The majority of patients in both groups were diagnosed on the basis of X-rays (82% 
in the community- and 57.1% in the facility-based group). 
Patients for whom an HIV test result was available were extremely likely to be HIV 
positive in both groups (80% in the facility-based and 84.6% in the community-based 
group), however the number of available test results was low. 
Amongst the sputum-positive patients, the community-based group was shown to 
have a cure rate of 95 percent (versus 37.1% in the facility-based group). 
Patients in the community-based group remained longer on TB treatment than the 
ones in the facility-based group (5.7 vs 5.0 months). However, the community-based 
group had a higher percentage of retreatment cases (22.4% versus only 12.7% in 
the facility-based group). 
 
5. CONCLUSION:  
This study suggests that community-based DOTS offers a better cure rate (95%) and 
completion of therapy (52%).  The longer duration of treatment observed in the 
community-based group could be partly due to its relatively higher number of 
retreatment cases as compared to facility-based group.  
An extremely high HIV rate (> 80%) has also been found in the TB-patient population 
in both groups. 
Community-based DOTS offers an alternative way for patients who do not have easy 
access to the clinics, provided the government strengthens the system and takes 
over recruitment as well as monitoring and motivation (incentives) of community-
health workers. 
There is also a growing concern with the relatively high number of patients defaulting 
or failing treatment in this group and further studies are needed particularly 
.retrospective to explore the matter. 
. 
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1. INTRODUCTION, BACKGROUND AND 
MOTIVATION 
The KWAZULU NATAL (KZN) Province is the epicentre of South Africa’s HIV/AIDS 
epidemic as well as of a severe form of tuberculosis (TB). The tuberculosis 
prevalence in the province is now beyond epidemic proportions. 
In 2006, a study conducted at Tugella ferry (a rural small town in KZN) provided the 
following results: TB Sputum cultures were performed on 1,539 patients with 542 
(35%) positive and 995 (65%) negative cultures. 221 (40%) patients were diagnosed 
with multi-drug resistant (MDR-TB) and 53 patients (24%) among MDR-TB were 
extensively drug-resistant tuberculosis (XDR-TB) 1.  
Up to the year 2007, more than 1,000 TB cases per 100,000 people have been 
recorded in the province. "Any ratio of more than 200 cases per 100,000 people is 
regarded as an epidemic”.2 
KZN is facing an epidemic of complicated tuberculosis never seen in South Africa.  
This alarming and explosive situation emphasizes the need for a comprehensive 
plan to successfully tackle and halt this epidemic. The increasing number of 
tuberculosis cases seen at Vryheid hospital’s OPD and Medical wards (50 or more 
cases every month: new, defaulters and complicated Tuberculosis) has prompted 
me to indirectly assess the effectiveness of community-based directly observed  
treatment short - course strategy (DOTS) by comparing the outcomes of the 2 types 
of DOTS: community- versus facility-based DOTS. Some authors consider 
community-based DOTS to be a better approach for complicated tuberculosis.  
1.1. DEMOGRAPHY 
The study was conducted at 2 major primary health care clinics: BHEKHUZULU and 
MASON Clinics situated at VRYHEID. VRYHEID is a small town in the ABAQULUSI 
municipality in the ZULULAND district. It lies southward along the R33 in the valley 
at the foot of the Zungwini Mountain. It is the centre of coal mining and cattle farming 
in the district. Vryheid has an urban population of 24,670 and is Zululand’s main 
commercial, industrial and business centre, with a reasonably well-developed 
physical, social and institutional infrastructure. It is well located at the intersection of 
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the major transport routes, which traverse the region. The population of Vryheid has 
a gender profile of 52.35 % male and 47.65 % female, with a poverty level of 32.8 %. 
It has an unemployment rate of 59.4%, with only 15.59 % working class.  
1.2. DOTS  
The directly observed therapy strategy is defined as a strategy to ensure patient 
compliance where a health worker or the designated person (community health 
worker) watches the patient swallow each dose of prescribed drugs. 
In 1980, Karel Styblo developed the essential components of DOTS 6 
The 5 components of the WHO’S DOTS strategy are  
1. Political and administrative commitment. 
2. Case detection, primarily by microscopic examination of sputum of patients 
presenting to health facilities. Access to quality- assured TB sputum 
microscopy for case detection among persons presenting with constitutional 
symptoms of TB. Special attention should be paid to case detection (TB) 
amongst HIV infected patients and other high risk groups such as household 
contacts of infectious patients and people in institutions.  
3. Standardized short-course chemotherapy to all cases of TB, given under 
direct supervision and patient support (DOT). It is called “proper case 
management”. The SA Tuberculosis Control Programme recommends 6 
months therapy for newly diagnosed TB patients. The duration of 8 months is 
the standard for TB retreatment or treatment failure, daily streptomycin 
injections are added for the initial 2 months of treatment. TB drugs are taken 5 
days per week.26 
4. Adequate supply of good quality drugs: uninterrupted supply of quality- 
assured drugs with reliable drug procurement  and distributions systems 
5. Systemic monitoring and accountability for every patient diagnosed; recording 
and reporting systems are crucial for the evaluation of the outcomes of every 
TB patient, and for the assessment of the overall programme performance. It 
forms the backbone of a systematic programme monitoring and resolution of 
identified problems. 
 10 
The aims of DOTS are summarized as follows: 
- Cure rates of up to 95% 
- Prevention of MDR/XDR TB emergences. 
- Improvement of quality of life and longevity of AIDS patients by TB control. 
South Africa (SA) has started the implementation of its DOTS program in 2001. 
MDR/XDR TB constitutes a growing threat to the global control of tuberculosis and 
impacts negatively on health workers as well as families and communities at large. 
Treating MDR/XDR tuberculosis is costly in terms of hospital stay and medications. 
In February 2008, the World Health Organization released its fourth global report on 
anti-TB drug resistance, which indicated that the number of MDR TB cases 
worldwide was increasing and the highest ever reported (489,139 cases in 2006) 
and that XDR TB had been reported in 45 countries. A critical need exists for new 
drugs and new drug regimens to address this growing challenge with emphasis on a 
comprehensive and integrated approach. The Global Alliance for TB Drug 
Development, of which CDC is a member, continued to make progress in this area in 
2007, with new candidate drugs moving forward in clinical trials. The WHO has 
recommended the application of the DOTS strategy for prevention of complicated 
tuberculosis in developing countries. 
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2. AIMS AND OBJECTIVES 
2.1. AIM 
To evaluate the effectiveness of DOTS strategy by comparing the outcomes of 
tuberculosis treatment of patients under DOTS at VRYHEID during 2007: facility-
based versus community-based DOTS. 
2.2. OBJECTIVES 
1. To determine the cure rate of patients under DOTS at Vryheid during 2007. 
2. To evaluate and compare the treatment outcomes between community-based and 
facility-based DOTS at Vryheid. 
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3. OVERVIEW OF THE LITERATURE REVIEW 
Tuberculosis is an important cause of death in the world. One of the major reasons 
for failure of tuberculosis treatment in African nations has been poor compliance with 
therapy, with resulting low treatment completion and cure rates. It is the leading killer 
of HIV-infected Africans. Tuberculosis can be controlled by applying the WHO’s 
directly observed therapy, short-course (DOTS) strategy. This strategy is aiming at 
detecting at least 70% of new smear positive tuberculosis cases and curing at least 
85% of these.  DOTS strategy was described by WHO at its introduction as the most 
important public health breakthrough of the decade in terms of lives saved. It is also 
one of the most” cost-effective of all health interventions” according to World Bank. 
Application of the WHO DOTS strategy can prevent drug-resistance 3;  
Two types of DOTS have been described: the facility-based DOTS (FACDOTS) and 
the community-based DOTS (COMDOTS) 
The FACDOTS is defined as the observation of the intake of tuberculosis drugs at 
the health facility by a health worker. It is referred to as the conventional method. In 
contrast, community-based DOTS (COMDOTS) is the administration of TB drugs by 
a trained member of the community. The latter approach was introduced to 
overcome some of the adherence barriers such as accessibility and as an attempt to 
improve the cure rates of tuberculosis treatment. Limited studies conducted in South 
Africa and Tanzania did not show much difference between these types in terms of 
treatment outcomes and cure rates, calling for further studies.4; 5 
 
3.1. TB and HIV  
HIV-infected individuals are at least 30-fold more likely to develop reactivation 
tuberculosis as HIV progresses .They are also more susceptible to exogenous 
infection in populations with a high prevalence of tuberculosis. Active tuberculosis 
accelerates the natural dynamics of tuberculosis epidemics. The risk of developing 
tuberculosis in HIV infected adults is 3 to 8% annually, giving a cumulative lifetime 
risk of 80% or more. In sub-Saharan Africa, 20 to 70% of all new adult cases and 10 
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to 40% of children with TB are HIV infected. The interaction of tuberculosis and HIV-
infected individuals is associated with increased HIV replication, possibly mediated 
by enhanced expression of pro-inflammatory cytokines such as tumour necrosis 
factor- alpha. Reactivation of latent tuberculosis is believed to be the major 
mechanism leading to tuberculosis in HIV-infected persons. HIV is the most 
important known risk factor for progression from latent TB infection (LTBI) to TB 
disease. The Centers for Disease Control and Prevention (CDC - a United States 
federal agency under the Department of Health and Human Services based in 
Atlanta) recommend routine screening for HIV for all persons with TB or LTBI at the 
initiation of TB or LTBI treatment11. The CDC continues to work with domestic and 
international partners to increase awareness of TB/HIV co-infection and improve the 
integration of TB/HIV health-care services. In many African countries, half or more of 
tuberculosis patients are now infected and it is important to note that persons with 
HIV infections are at increased risk of rapid progression following primary infection or 
re-infection, and also from reactivation of latent infection with Mycobacterium 
tuberculosis. More strategies are needed to curb the HIV transmission (active and 
passive case detection; prevention of nosocomial transmission) and reactivation 
(preventive therapy). The high burden of other HIV related disease in patients with 
tuberculosis, such as other bacterial infections, toxoplasmosis and other 
manifestations of AIDS, requires a well integrated TB-HIV/AIDS program including 
the provision of HIV/AIDS care. HIV/AIDS in Africa poses severe challenges of 
purpose and identity to tuberculosis control programmes, which have not adapted to 
the altered realities of the HIV/AIDS era. 
HIV infection could rapidly become a risk factor for drug-resistant TB if HIV infected 
patients become co- infected with drug-resistant mycobacterium tuberculosis or if 
HIV infections become a risk factor for acquired resistance as the co-epidemics 
evolve. Therefore efforts to prevent active TB in the large population of persons 
infected by TB and HIV co-epidemics through the use of preventive should be 
pursued. Policy makers in low income countries with TB and HIV co-epidemics 
should maintain investment in DOTS implementation but should also realise that TB 
case fatality rates will continue to rise and that program performance may be better 
judged using rates of drug resistant TB6. 
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A well implemented DOT strategy amidst rapidly increasing prevalence of HIV in sub 
Saharan Africa may succeed in controlling drug resistant TB but may fail to control 
the TB case rate. The apparent ineffectiveness of the current DOTS strategy in 
lowering TB rates in the population is likely due to the fact that most of the TB cases 
now result from endogenous reactivation of latent tuberculosis in HIV infected 
persons. The role of DOTS in controlling the TB case rate in the era of HIV is to 
convert TB cases to a non-infectious state as soon as possible in order to reduce 
transmission especially to HIV infected. DOTS, however, cannot prevent 
development of active TB in persons who were infected with Mycobacterium 
Tuberculosis many years earlier6.  
3.2. DOTS AND DRUG-RESISTANT TUBERCULOSIS 
Multi-drug resistant tuberculosis (MDR-TB) is a growing hazard to human health 
world wide and threatens the control of tuberculosis. It is a man-made problem and 
its emergence can be prevented by prompt diagnosis and effective treatment of all 
TB cases. Adoption of directly-observed therapy short course (DOTS) to prevent the 
resistant/ multi-drug resistant strains and careful introduction of second line drugs to 
treat patients with MDR-TB are the top priorities5. Standard short course 
chemotherapy, based on first line drugs, is inadequate for some patients with drug- 
resistant tuberculosis TB. Therefore it should be modified in some settings to identify 
drug-resistant case sooner and to make use of second-line drugs in appropriate 
treatment regimens. The emergence of MDR is also a symptom of ineffective 
tuberculosis control. Moreover, the  treatment of MDR-TB is difficult, expensive and 
requires prolonged therapy with more toxic second-line drugs which are not available 
at most tuberculosis control programs in developing countries 7; 8. 
The development of the DOTS strategy is a milestone in tuberculosis (TB) control at 
the global and national levels but it is challenged by the following weaknesses which 
need to be overcome: built on case management, sustaining commitment, 
competing priorities, the threat of HIV, maintaining high quality of care and 
preventing drug resistance, building human resource capacity, improving diagnosis 
and fostering operations research. The ability to address these challenges will 
determine the success or failure of the Global Plan to Stop TB 2006 - 2015 8; 9; 10. 
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The treatment success with WHO DOTS strategy was 83 % of the world’s population 
living in countries or part of countries covered by this strategy by the end of 2004 but 
could not reach the target of 85 %. In the 2003 DOTS cohort study, treatment 
success was below average in the African Region (72%), which can be partly 
attributed to occurrence of HIV co-infection, and in the European Region (75%), 
partly due to drug resistance. Drug resistance, specifically multidrug resistance and 
extensive drug resistance, is a serious threat to public health in all countries, 
especially where the highest rates of multidrug resistance are presently 
accompanied by a rapid increase in HIV infection. Based on the experience of the 
first projects approved by the Green Light Committee, the treatment success of 
patients with multidrug-resistant tuberculosis (MDR-TB) is lower than that of drug-
susceptible cases, but nevertheless reaches 70%. The collaborative effort of 
different organizations, professionals and communities is needed to address the 
development and spread of multidrug resistance and extensive drug resistance, 
which combined with the epidemic of HIV infection is one of the barriers to dealing 
effectively with TB. This effort should be directed towards facilitating the diagnosis 
and treatment of TB patients, in particular by improving access to drug susceptibility 
testing and strengthening treatment delivery by rigorous adherence to DOTS as 
outlined by the Stop TB Partnership 9, 10. DOTS constraints include: problems with 
health facilities, patients, drugs and the disease itself. The effective involvement of 
private healthcare providers is imperative to achieve better geographical and patient 
coverage for the implementation of DOTS.10 
The strong association between HIV and TB in sub-Saharan Africa is responsible for 
the massive increase in the incidence of TB observed in this region in the last 20 
years. Diagnosis of TB in resource-poor countries is largely based on sputum-smear 
microscopy and chest radiography, although these methods lack sensitivity or 
specificity, especially when used on HIV-infected patients. Unfortunately, countries in 
sub-Saharan Africa are falling short of the World Health Organization's targets for 
case detection and treatment. This failure is, in turn, making the achievement of the 
Millennium Development Goals for TB--to ensure that the incidence of TB is falling 
by 2015 and to halve the prevalence of TB and the annual number of TB-attributable 
deaths between 1990 and 2015-less likely. To improve the performance and impact 
of TB-control programs, in the face of HIV co-infection and other constraints on 
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DOTS, the World Health Organization has launched ’’ the revised Stop TB 
Strategy'’. The new strategy, to be implemented via the Global Plan to Stop TB 
(2006-2015), includes intensified TB-case finding, treatment of latent TB infection 
with Isoniazid, prevention of HIV infection, cotrimoxazole preventive therapy, and 
antiretroviral therapy10; 11; 12; 13.  
The DOTS- Plus strategy for the management of Multi-drug resistant (MDR)-TB 
and the establishment of The Green Light Committee to review project applications 
in this area are also initiatives taken to curb the problem of drug-resistance. 
Treatment of MDR-TB is difficult, complicated, expensive, challenging and needs 
skills and experience. All measures should be taken to persuade and encourage 
patients not to stop treatment despite its discomforts to prevent morbidity, mortality 
and transmission of MDR-TB. The current proposal of the WHO DOTS plus 
highlights the need for a comprehensive management strategy to control MDR-TB. 
The adoption of DOTS to prevent the resistant/ multi-drug resistant strains and 
careful introduction of second line drugs to treat patients with MDR-TB are the top 
priorities for the proper control of MDR-TB. A DOTS alone is unlikely to control 
tuberculosis in sub-Saharan Africa; however one major achievement of the 
implementation of DOTS is to limit the development and spread of drug-resistance.  
It is also important to note that women are at increased risk of progression to 
disease during their reproductive years. The fear and stigma associated with 
tuberculosis have a greater impact on women; often leaving them in a more 
precarious social and economic position25. Tuberculosis in women creates orphans, 
impoverished families and reduces the economic development of society. Gender 
differentials exist in reporting and diagnosing TB and passive case finding likely 
leads to failure to diagnose TB in women. Therefore, Tuberculosis Control programs 
should be sensitive in the constraints faced by women in accessing health care, in 
order to empower women to commence and complete treatment25. 
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4. STUDY DESIGN AND METHODOLOGY 
 4.1. RESEARCH QUESTION 
Does Community-based DOTS strategy offer better tuberculosis treatment outcomes 
than the facility- based DOTS program? 
4.2. STUDY DESIGN 
It is a retrospective (non concurrent or data base) COHORT study.  
The research was conducted at (data were retrieved from the TB registers at) 
BHEKUZULU and MASON Clinics, in VRYHEID at ABAQULUSI municipality. The 
study looked at the cure rate and outcomes of tuberculosis treatment of patients 
under DOTS strategy at VRYHEID: facility- versus community based-DOTS.  
It is an observational assignment study as patients were already allocated to 
community- and facility-based DOTS at the time of extraction of data. 
The following main outcomes were assessed: cured, completed, defaulted, relapsed, 
failed, and died. 
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5. SAMPLING, DATA COLLECTION AND 
ETHICAL CONSIDERATIONS 
5.1. SAMPLING 
The study was conducted at VRYHEID, in the Kwazulu-Natal province and data were 
collected from TB registers of 2 primary health care facilities (Mason and Bhekuzulu 
clinics) from January to December 2007. 
The diagnosis is usually made at the clinics or at Vryheid hospital and patients were 
thereafter assigned to one of the 2 groups of the study, based on their location or 
access to the health facility (near to or far from the clinic) and the preference of the 
patients. In both, facility- and community-based groups, patients collected their 
medications at their assigned clinic on a monthly basis. However, in the community-
based group, patients are visited by the community health workers on a weekly basis 
to count the pills, double check the ticking process, discuss patient’s problems and 
report back to the mother clinics. Daily supervision of TB drug-taking (5 days per 
week) and ticking of the green TB card is done by family members or by the patients 
themselves. 
The severe shortage of community health workers versus vastness of areas to cover 
has made the coverage of all catchment areas by community health workers difficult. 
Therefore there are some patients who opted for community-based DOTS and who 
are visited by mobile clinics monthly. 
It is sad to note that community health workers were recruited and paid by non-
governmental organizations and attached to the clinics. Clinics operational managers 
were adamant to the fact that not only they did not have control on  community 
health workers activities but also that some of the community health workers did not 
do their jobs properly (e.g. regular visits to patients) because other commitments 
such as attending to their own lucrative jobs. Serving 2 masters resulted in poor 
supervision of patients. It is also important to mention that community health workers 
were not regularly up-skilled. 
Patients on retreatment (after cure, relapse or failure ) regimen received their daily 
injection of streptomycin (5 days per week) at the clinics for the first 2 months of the 
treatment and may thereafter continue either in a facility- or a community-based 
group. 
Following criteria were used in sampling patients for the research: 
Inclusion criteria: 
- Age : children and adults 
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- Sex: Female or male 
- Newly diagnosed, relapse, treatment failure or defaulting 
- Pulmonary or extra-pulmonary tuberculosis 
Exclusion criteria: 
- Confirmed MDR/XDR patients on therapy, because these patients are 
admitted and treated in specialized centers where strict facility-based DOTS 
are applied. 
 
A sample size of 392 (N=392) patients for each group was estimated to be needed to 
determine a difference of 10 % (with a power of 90%) between the two groups of the 
study: community-based versus facility-based DOTS.  
5.2. DATA COLLECTION 
The data for the study were extracted from the two clinics’ TB registers by clerks. 
The clerks did not receive any specific training for this study, but worked hand in 
hand with the TB coordinator nurse and were bound to confidentiality. 
 The data collection sheet included the following information:       
- Code 
- Age 
- Gender: female or male 
- Duration of treatment 
- HIV status (if available) 
- TB Status: newly diagnosed, retreatment after cure, default, failure and other 
types 
- Treatment outcomes: completed, cured, failure, default, lost to follow-up, died, 
transferred, moved out, interrupted 
- Diagnosis mode:  Sputum AFB , CXR results, biopsy 
- Sputum microscopy, culture and sensitivity results. 
The study included 809 patients, with 401 patients retrieved from Mason and 408 
from Bhekuzulu clinic. 
The South African National Tuberculosis Control Programme provides the following 
definitions of concepts used in TB treatment outcomes:  
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- Cured (C): defined as patient who initially was smear positive, converted to a 
smear negative at or 1 month prior to completion of treatment and on at least 
on one previous occasion. 
- Treatment Completed (TC): patient who has completed treatment but does 
not have bacteriologic proof of cure. 
- Treatment Defaulted (TD): a patient whose treatment is interrupted for 2 
consecutive months or more. 
- Treatment Failure (TF): patient who remains smear-positive at 5 months or 
later during treatment. 
- Died (D): patient who dies for any reason during TB treatment. 
- Treatment interrupted: when TB treatment has been interrupted for less than 
4 weeks. 
- Transfer out: when a TB patient has been transferred to another sub-district 
health district, province or country and for whom treatment outcome is not 
final. 
- Moved: when a TB patient has moved from one health facility to another 
within the same sub- district. This outcome is not counted as final. 
5.3. DATA ANALYSIS 
The CHI-SQUARE, MANN-WHITNEY and ANOVA tests were used and assisted in 
comparing the 2 modes of DOTS, focusing specifically on the cure rate and the 
outcomes of TB treatment. 
5.4. ETHICAL CONSIDERATIONS 
Confidentiality and privacy of patients were observed by using a coding system. Only 
the TB clerks at the site of collection of data had access to these records 
A waiver for informed consent was obtained from the ethics committee of 
Stellenbosch University as well as approval from the KZN health authorities. 
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6. RESULTS 
The study was conducted at Bhekuzulu and Mason clinics. Vryheid TB clinic was not 
part of the study, as its 2007 TB-register was missing at the time of collection of 
data. 
A sample of 392 patients in each group was aimed for. 
 
Altogether 809 cases were included in the research, with 401 at Bhekuzulu clinic and 
408 at Mason clinic. 
6.1. DEMOGRAPHIC CHARACTERISTICS 
The following demographic parameters were considered in the study: 
- Age 
- Gender 
- HIV status  
- Mode of Diagnosis 
- TB status or category 
N.B. The residuals (observations minus the DOT group mean) in the analysis of age 
and duration of treatment are not normally distributed. Therefore the results from 
non-parametric tests (i.e. the Mann-Whitney tests) will be used to analyze the 2 
variables 
Table 1. AGE DISTRIBUTION 
 All patients 
Mean(CI 95%) 
Facility based  
Mean (CI 95%) 
Community based 
Mean (CI 95%) 
P value 
Age 
(years) 
30.6 (29.5- 
31,7) 
31.2 (29.7- 
32.6) 
30.1 (28.5 – 31.6) 0.30 
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The comparison of age between the 2 groups of the study has shown no significant 
difference (p value = 0.30).  
Table 2. MANN-WHITNEY TEST FOR AGE 
 
 
 
Variable 
Mann-Whitney U test :by variable DOTS type 
Marked tests are significant p <0.05 
Rank Sum 
community 
Rank Sum 
facility 
U Z 
adjusted 
p- level 
 
Valid N 
Communit
y 
Valid N 
Facility   
Age  161584.5 166060.5 80983.5
0 
-0.246833 0.8650
37 
401 408 
In addition to the chi-square test, the Mann-Whitney test was used as there was no 
homogenous distribution of age. The Mann-White test has also confirmed the lack of 
difference between the 2 groups. 
Table 3. GENDER DISTRIBUTION 
  All patients Facility based 
DOTS 
Community 
based DOTS 
P 
value 
  N % N % N %  
 
 
0.13 
 
GENDER 
 
Female 
 
400 
 
49.4 
 
191 
 
46.8 
 
209 
 
52.1 
  
Male  
 
409 
 
50.6 
 
217 
 
53.2 
 
192 
 
47.9 
The community-based DOTS had 52.1 percent of male patients and 47.9 of female 
involved in the study, whereas 46.8 percent were male patients and 53.2 percent 
female in the facility-based DOTS.  
The study did not show any major difference between the 2 groups that could affect 
the results (p value= 0.13) 
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Table 4. HIV STATUS AND MODE OF DIAGNOSIS 
  All patients  
N= 809 
Facility 
Based  
N= 408 
Community 
based 
N= 401 
P value 
  N % N % N %  
< 0.01 
 
 
HIV status 
Known 148 18.3 5 1.2 143 35.7 
Unknown 661 81.7 403 98.8 258 64.3 
HIV rate 
(of those 
tested) 
Positive  125 84.5 4 80 121 84.6  
Negative  23 15.5 1 20 22 15.4 
DIAGNOSTIC 
MODE 
CHEST      X-
RAYS 
564  233 57.1 331 82.5  
 
0.0000 
SPUTUM 244  175 42.9 69 17.2 
 
- 35.7% of patients involved in community-based DOTS had their HIV tests 
done but the testing rate in facility is only 1.2%. It is also important to note that 
both groups had a high rate of unknown results (98.8% in facility- and 64.3% 
for community-based). The difference in the testing rate between the 2 groups 
is statistically significant ( p= < 0.01) 
- In the community-based treatment group, a significantly smaller percentage of 
patients had been diagnosed with positive sputum (17.2% versus 43% in the 
facility-based treatment group). The majority of cases in both groups was 
diagnosed on grounds of chest x-rays (82.5% in the community group, 57.1% 
in the facility-based group) 
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Table 5. TB STATUS (CATEGORY) 
 Community- based 
group 
Facility- based 
group 
Total 
  N (%) 
401 
 N (%) 
409 
 
809 
New cases  311 (77.6%) 356 (87 %) 667 (82.4) 
Retreatment cases 90 (22.4%) 52 (13%) 142 (17.6) 
The community-based group had 77.6% new cases and 22.4% of retreatment but 
the number of retreatment is smaller in facility-based (87% new cases and 13% 
retreatment cases). 
 
6.2. OUTCOMES OF TUBERCULOSIS TREATMENT 
In this section 3 categories of results will be presented: 
- Outcomes of TB treatment 
- Tuberculosis cure rate 
- Duration of TB treatment 
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Table 6. TB TREATMENT OUTCOMES 
  Community 
based group 
Facility 
based group 
All patients P value 
 N= 401 
N (%) 
N= 408 
N (%) 
N= 809 
N (%) 
significant 
if < 0.05 
(*) 
Cured  66 (16.5) 65 (16.2) 131 (16.2) 0.93038 
Completed 209 (52.1) 154 (37.7) 363 (45) 0.00389* 
Defaulted 18 (4.5) 7 (1.7 ) 25 (3.1) 0.02781* 
Died  57 (14.2) 25 (6.1) 82 (10.1) 0.00041* 
Failed 24 ( 6) 15 (3.7) 39(5) 0.14954 
Retreatment after 
cure 
3 (0.7) 0 3 (0.4)  
Lost- to follow-up 7 (1.7) 0 7 (1)  
Moved 11 (2.7) 0 11 (0.1) 0.00091* 
Transferred 2 (0.5) 0 2 (0.2)  
Interrupted 4 (1) 142 (34.8) 146 (18) 0.00000* 
Table 5 compares the outcomes of TB treatment within the group and between the 2 
groups. 
 52% of patients in community-based completed their TB treatment and 
only 37.7% in facility group. 
 14% of patients died in community-based DOTS versus 6.1% in facility-
based group 
 4.5% of community-based group defaulted medications as compared to 
1.7% in facility group. 
 34.8% of facility-based DOTS interrupted treatment whereas the 
percentage is lower in community-based (1%) 
 Community –based group had a failure rate of 6% versus 3.7% in 
facility. 
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Table 7. TUBERCULOSIS CURE RATE 
 Community based Facility based Total 
Cured (i.e. sputum 
negative at 5 or 6 
months of therapy) 
 
N= 66 
 
N= 65 
 
131 
Total sputum 
positive at the 
beginning 
 
69 
 
175 
 
244 
 
Cure rate 
 
95.65 % 
 
37.14%. 
 
                                         
The cure rate (in percentage) is calculated as follows: 
Cure rate (%) = Total number of sputum negative at 5-6 months of TB treatment 
                                Total number of sputum positive at onset of TB therapy. 
Community-based treatment group has shown to have a higher cure rate (95.65%) 
as compared to facility-based DOTS (37.14%). 
Table 8. DURATION OF TREATMENT 
 All patients 
Mean (CI 95 
%) 
In Facility   
Mean (CI 95%)                       
In Community  
Mean (CI 95%) 
P value 
Duration of 
treatment 
(months) 
 
5.35 ( 5.2- 5.5) 
 
5.01 ( 4.8- 5.2) 
 
5.7 ( 5.5- 5.9) 
 
0.00003 
 
It is important to note that duration of treatment means the effective duration of 
treatment including drop-outs by deaths or loss-to-follow-up. 
The table above shows that patients in the community-based group on average 
remained significantly longer on treatment than those in the facility-based. 
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Table 9. MANN-WHITNEY TEST FOR DURATION OF TREATMENT 
 
 
 
Variable 
Mann-Whitney U test :by DOTS type 
Marked tests are significant p <0.05 
Rank Sum 
community 
Rank Sum 
facility 
U Z 
adjusted 
p- level 
 
Valid N 
Communit
y 
Valid N 
Facility 
      
 
Duration  
 
179908 
 
147737. 
 
64301.0
0 
 
5.454186 
 
0.0000 
 
401 
 
408 
 
This test addresses the lack of a normal distribution in the duration of treatment as 
demonstrated by other tests. 
P value is 0.0000 for duration of treatment; meaning that there is a significant 
difference between the 2 groups. 
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7. DISCUSSION 
7.1. MAIN FINDINGS 
7.1.1. Duration and outcomes of TB treatment 
Community-based DOTS has shown to have a higher cure rate (96.5%), a higher 
number of patients who have completed TB therapy (n= 209) and a higher mean 
duration for treatment (5.7 months).  
Achieving a cure rate up to 95 percent is one of the aims of the DOTS strategy as 
outlined by the WHO at its introduction. COMDOTS with its 96.5% has performed 
beyond the expectation. 
There are, however, some confounding factors concerning the duration of treatment. 
The community-based group in the study was shown to have 22.4% of retreatment 
cases versus only 13.6% in the facility-based group. Since the retreatment-cases are 
supposed to receive a longer treatment according to the national protocol (8 versus 6 
months), this might affect the resulting average treatment duration.  
In both groups medications (TB-drugs) are dispensed on a monthly basis, but 
patients take their drug 5 days per week, supervised mostly by family members or 
themselves who ticked on the green card. It is important to note that in the 
community- based group patients are visited by community health workers on a 
weekly basis to discuss their concerns, and a feedback report is given to the mother 
clinic every week. Patients who were assigned to the community-based group and 
who live in an area hard to reach benefit from a monthly mobile clinic visit to address 
their concerns (such as side effects, counting of pills, ticking of cards, change of 
regimen and referral). Investigations are done at the end of the intensive and of the 
continuation phase or at any other time the need arises. 
The weekly visit to patients, for support, motivation and discussion of their concerns 
by community health workers in the community-based group may play a vital role in 
the achievements noticed in this group. However, it is important to note that 
community health workers who have other lucrative jobs and may not have time to 
visit patients regularly could either underreport or exaggerate some of the figures, 
which will distort the true impact of community-based DOTS. 
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It is important to note that in either group, patients who were diagnosed with 
treatment failure, relapse or who previously had defaulted treatments were initiated 
on the 2nd-line regimen according to the South African national tuberculosis 
programme guidelines, while sputa specimens were collected and sent to the 
laboratory for further analysis (microscopy, culture and sensitivity). Ambulatory 
patients received injections of streptomycin at the clinic for the initial 2 months, 
whereas very sick and non-adherent patients were admitted to Vryheid district 
hospital for a short stay while transfer arrangements to nearby hospitals with TB 
ward facility (MOUNTAIN VIEW and SILOE hospitals) were made. 
Confirmed MDR patients and suspected XDR patients were admitted at 
THULASIZWE hospital (specialized TB hospital), where they received supervised ( 
health workers) and specialized TB treatments. Confirmed XDR patients were 
directly sent to the special TB unit of King George Hospital in Durban.  
However, the study shows that community-based DOTS is also associated with a 4.5 
percent rate of defaulters versus 1.7 percent in the facility-based group with 
treatment failure rate is a bit higher in the community-based (6%) as compared to the 
facility-based group (3.7%). 
Lastly, the community-based group has shown a drastically lower treatment 
interruption rate (1%), compared to the facility-based group (34.8%). 
7.1.2. Age and Gender distribution 
Age and gender were fairly distributed between the 2 groups of the study and no 
significant difference in age and gender between community and facility- based 
DOTS has been shown. Patients in the community group had a mean age of 30 
years versus 31 in facility. 
46.8 percent of female and 53.2% of male patients were recorded in the facility- 
based group versus 52.1% of female and 47.9% of male patients in the community-
based group. 
 
 30 
7.1.3 Mode of diagnosis of Tuberculosis  
There is a significant difference between the 2 groups of the study in relation to the 
mode of diagnosis. Nevertheless, it is important to note that TB patients were 
diagnosed (CXR, sputum or other means) at Vryheid hospital and down-referred via 
Vryheid Hospital’s TB clinic to a primary health care clinic for commencement of 
treatment. The choice of clinic is based on the location and preference of the patient. 
7.1.4. HIV status 
The difference in the number of patients tested for HIV status between the 2 groups 
is due to an administrative fall-out (lack of HIV status column in the 2007 TB 
register). 
However, the high rate of HIV (>80%)  in those patients with documented HIV results 
is in line with the high rate of immuno-suppression that has to be expected given the 
above described modes of diagnoses (chest X-rays/ clinical rather than sputum).  
 
7.2. COMPARISON WITH OTHER STUDIES 
This study suggests that community-based DOTS offers better TB treatment 
outcomes with regard to cure rate and interruptions of treatment. 
These findings do not exactly match the findings of 2 previous studies4;5 conducted in 
Tanzania and South Africa which concluded that there were no differences between 
the 2 strategies (community- and facility-based DOTS).  
However, this study confirms the one of  the findings of the above mentioned studies 
stating that community-based DOTS may constitute an alternative way of TB 
treatment in rural areas when distance between the facility and the community is an 
issue. 
7.3. STRENGTHS AND WEAKNESSES OF THE STUDY  
There has so far not been any study in the KZN province that has evaluated the 
effectiveness and efficacy of community- versus facility-based DOTS by 
retrospectively looking at their treatment outcomes. Therefore this study has given 
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an opportunity to compare TB treatment outcomes between community- and facility-
based DOTS and calls for further studies in this field. 
The diagnosis of tuberculosis in this study was mainly made on X-rays grounds and 
not on sputum as recommended by the national and international guidelines. KZN 
province has the highest prevalence of HIV/AIDS in the country, making the 
diagnosis of tuberculosis by sputum more difficult. It is important to note that both 
chest x-rays and sputum investigations in HIV patients, especially in those with 
advanced stages, lack specificity and sensitivity. 
This study was conducted at 2 main clinics in Vryheid: Mason and Bhekuzulu clinics. 
The diagnosis is made at the hospital and patients are down-referred to these 2 
clinics. Mason clinic focuses exclusively on patients who collect their medications at 
the facility (once per month). Bhekuzulu clinic is located in a BHEKHUZULU 
township in Vryheid and deals mostly (99%) with community-based DOTS. Patients 
are assigned to one of these clinics, based on their choice and accessibility to the 
health facility (distance between the clinic and their location). This type of 
assignment of patients could result in selection bias. 
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8. CONCLUSION AND RECOMMENDATIONS 
1. The COMDOTS strategy seems to offer better treatment outcomes in terms of 
cure rate (95%) and interruption rate than the FACDOTS approach. Although 
patients in the community-group appeared to remain longer on treatment, it is difficult 
to draw conclusion on this benefit as this group of the study had a relatively higher 
number of retreatment cases (that may in part explain the longer duration of 
treatment observed). There is a need for further studies to look at reasons behind 
the relatively high rate of defaulters and treatment failures seen in the COMDOTS 
group. Community-based DOTS can also be used as an alternative way of treating 
tuberculosis in areas where access to the health facilities is hampered by long 
distances between the community and the primary health care facilities. Continuing 
education of patients and the community regarding the availability and potential 
benefits of community-based DOTS may increase the uptake of this program for 
patients living far from the clinic. 
2. It is vital that the government takes over completely the recruitment and allocation 
of community health workers. This measure will not only allow the government to 
establish proper governance, but also a close monitoring of daily activities of 
community health workers. This category of staff is crucial for the success of the 
national TB program and should not be left in the hands of private organisations 
(NGO). They should report directly to the sisters-in-charge of clinics. There is also a 
need for motivation of community health workers and for the provision of regular in-
service training to keep up with national guidelines. Again, this calls for an active 
involvement of the government. The recruitment and training of a large number of 
community health workers by the government not only will result in daily visits to 
patients (not just weekly), but will also ease the burdens for patients living in areas 
hard to reach and may reduce the number of defaulters and treatment failures. This 
advocates the need for a complete shift of paradigm of visits to patients: from weekly 
to a daily visit in order to curb the increasing number of MDR/ XDR observed in our 
province. 
3. The facility-based DOTS should not be abandoned and can still be used for 
patients who are living within the neighbourhood of the clinic and are willing to collect 
medications at the clinic. It should be strengthened and amended to a daily 
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supervised swallowing of medications at the health facility. The success of the 
treatment and thus better outcomes should be the responsibility of both the patient 
and the health care provider.  
4. Sputum and chest x-ray investigations, found in my study as major modes of 
diagnosis of pulmonary tuberculosis, have been proven to lack specificity and 
sensitivity in areas with high prevalence of HIV and AIDS. Therefore it is paramount 
for the government of SA and its national Tuberculosis program to find alternative 
and reliable ways of diagnosing tuberculosis in patients infected with HIV/AIDS. 
5. The results of this study will be shared with the local managers, health workers 
and community to highlight the benefits of adhering to treatment in terms of TB 
management outcomes.  
 34 
9. REFERENCES 
1. Gandhi NR. Extensively drug-resistant tuberculosis as a cause of death in patients 
co-infected with tuberculosis and HIV in a rural area of South Africa, Lancet 2006; 
368:1575. 
2. www.int.iol.co.za/general/news 
3. Wing Wai V. Directly Observed Therapy, Short Courses: “The Best way to prevent 
Multi-drug resistant tuberculosis”. Chemotherapy 1999, proquest medical 
libraries:26. 
4. Lwilla F, Schellenberg D, Masanja H, et al. Evaluation of the efficacy of 
community-based vs. institutional-based direct observed short-course treatment for 
the control of tuberculosis in Kilombero district, Tanzania. Tropical Medicine and 
International Health, March 2003; 8(3):204–10  
 
5. Lewin S, Dick J, Zwarenstein M and Lombard CJ. Staff training and ambulatory 
tuberculosis treatment outcomes: a cluster randomized control trial in South Africa. 
World Health Organization. Bulletin of WHO; Apr 2005; 83(4):250 
6. Kenyon TA, Mwasekaga MJ, Huebrier R, Rumisha D, Binkin N, Maganu E. Low 
levels of drug-resistance amidst rapidly increasing Tuberculosis and Human 
immunodeficiency virus Co epidemics in Botswana. Int J Tuberc Lung Dis 1999; 
3(1):4-11. 
7. Johnson JL and Adult JJ. Tuberculosis overview: African versus western 
perspectives. Current opinion in Pulmonary Medicine 2000; 6:180-6. 
8. Frieden TR, Munsiff SS. The DOTS strategy for controlling the Global 
Tuberculosis Epidemic. Clin Chest Med 2005; 26:197-205. 
9. Prasad R. Management of Multi-drug resistant tuberculosis: Practitioner’s View. 
Indian J 2007; 54(1):3-11 
10. Espinal MA et al. Standard short course chemotherapy for drug- resistant 
tuberculosis: treatment outcomes in 6 countries. JAMA. 2000; 283:2537-45 
11. CDC. Provider-initiated HIV testing and counselling of Tb patients- 
LIVINGSTONE District, Zambia, September 2004—December 2006. MMWR 2008; 
57:285-9 
12. CDC. Revised technical instructions for tuberculosis screening and treatment for 
Panel physicians. MMWR 2008; 57:292-3. 
13. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the 
ATP synthatase of Mycobacterium tuberculosis. Science 2005; 307:223-7. 
 35 
14. Matsumoto M, Hashizume H, Tomishige T, et al. OPC- 67683. A nitro-
dihydroimidazooxaxole derivative with promising action against tuberculosis in Vitro 
and in mice. Plos med 2006; 3:e466. 
15. Enarson DA, Billo NE. Critical evaluation of the global Dots expansion plan, Bull 
world health organ, May 2007; 85 (5):395-8; discussion 399-403 
16. Blondal K. Barriers to reaching the targets for tuberculosis control: Multi- drug 
resistance tuberculosis. Bull world organ, May 2007; 85(5):387-90; discussion 391-4. 
17. Harries AD, Dye C. Tuberculosis. Ann Trop Med parasitol. 2006 Jul- Sep; 100 (5-
6):415-31. 
18. Leimane V, Leimans J. Tuberculosis in Lativia: Integrated DOTS and DOTS – 
plus programs. Euro surveill. 2006; 11(3):29-33. 
19. Okeke IN, Klugman KP, Bhutta ZA, Duse AG, Jenkins P, O’ Brien TF, Pablos- 
Mendez A, Laxminarayan R. Antimicrobial resistance in developing countries. Part II: 
strategies for containment. Lancet Infect Dis. 2005 Sept; 5(9):568-80. 
20. Deriemer K, Garcia-Garcia L, Bobadilla-del-Valle M, Palacios-Martinez M, 
Martinez-Gamboa A, Small PM, Sifuentes-Osornio J, Ponce-de-Leon A. Does DOTS 
work in populations with drug-resistant tuberculosis? Lancet 2005 April 2-8; 
365(9466):1239-45 
21. Chaudhury RR, Thatte U. Beyond DOTS: Avenues ahead in the management of 
tuberculosis. Natl Med J India. 2003 Nov- Dec; 16(6):321-7. 
22. Bergdorf MW. Control of drug-sensitive and (Multi)-resistant tuberculosis. Ned 
Tijdschr. v Geneskunde 2002 August 17; 146(33):1525-7. 
23. Murali Ms, Sajjan BS. DOTS strategy for control of tuberculosis epidemic. Indian 
J Med Sci. 2002 Jan; 56(1):16-8. 
24. De Cock KM, Chaisson RE. Will DOTS do it? A reappraisal of tuberculosis 
control in countries with high rates of HIV infection. Int J tubercul Lung Dis. 1999 
June; 3(6):457-65. 
25. Connolly M, Nunn P. Women and tuberculosis. World Health stat Q. 1996; 49(2): 
115-9. 
26. The South African National Tuberculosis Control Programme Practical 
Guidelines 2004. 
 
 
 36 
10. APPENDICES 
10.1. KZN HEALTH DEPARTMENT: HEALTH RESEARCH COMMITTEE 
APPROVAL LETTER 
 
 37 
10.2. STELLENBOSCH UNIVERSITY ETHICS COMMITTEE APPROVAL 
DOCUMENT 
 
